Editas Medicine (EDIT) Net Equity Issued and Repurchased (2015 - 2025)

Editas Medicine (EDIT) has 9 years of Net Equity Issued and Repurchased data on file, last reported at $17.1 million in Q3 2025.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $17.1 million in Q3 2025; TTM through Sep 2025 was $25.8 million, a N/A change from a year earlier, with the FY2023 full-year figure at $117.1 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased for Q3 2025 stood at $17.1 million, up from $7.2 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for EDIT reached as high as $249.5 million in Q1 2021 and fell as low as -$11000.0 in Q2 2021.
• Historically, Net Equity Issued and Repurchased has averaged $56.0 million across 3 years, with a median of $7.2 million in 2025.
• On a YoY basis, Net Equity Issued and Repurchased climbed as much as 100.88% in 2021 and fell as far as 100.01% in 2021.
• Year by year, Net Equity Issued and Repurchased stood at $1000.0 in 2021, then soared by 11709900.0% to $117.1 million in 2023, then sank by 85.36% to $17.1 million in 2025.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $17.1 million in Q3 2025, $7.2 million in Q2 2025, and $1.4 million in Q1 2025.